Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
25 Jul 2017 EMA Adopts a New Indication for Pembrolizumab Genitourinary cancers - Cancer Immunology and Immunotherapy
24 Jul 2017 EMA Recommends Granting a Marketing Authorisation for Atezolizumab Genitourinary cancers - Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
21 Jul 2017 FDA Grants Regular Approval to Blinatumomab and Expands Indication to Include Philadelphia Chromosome-Positive B-Cell Relapsed or Refractory Precursor ALL Haematologic malignancies - Anticancer agents & Biologic therapy
20 Jul 2017 ESMO 2017 Press Release: ESMO Awards recognise four outstanding oncologists
20 Jul 2017 Call for Independent Scientific Experts to Join EMA’s Pharmacovigilance Risk Assessment Committee Bioethics, legal and economic issues
19 Jul 2017 How Different Forms of Liquid Biopsies Can Be Exploited to Guide Patient Care? Translational research
19 Jul 2017 FDA Approves Neratinib for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer Breast cancer - Anticancer agents & Biologic therapy
18 Jul 2017 FDA ODAC Recommends Biosimilar Bevacizumab and Trastuzumab Anticancer agents & Biologic therapy
17 Jul 2017 FDA Grants Priority Review for Abemaciclib in Advanced Breast Cancer Breast cancer - Anticancer agents & Biologic therapy
14 Jul 2017 FDA Clears Expanded Use of Cooling Cap to Reduce Hair Loss During Chemotherapy Palliative and supportive care
13 Jul 2017 The EU-Funded MiRoR Project Will Transform Clinical Research Practice and Increase its Value Bioethics, legal and economic issues
12 Jul 2017 NICE Terminates Appraisals for Daratumumab with Lenalidomide and Dexamethasone, Bortezomib in Relapsed Multiple Myeloma, and Ibrutinib for Untreated CLL Haematologic malignancies - Anticancer agents & Biologic therapy
11 Jul 2017 FDA Approves L-Glutamine Powder for the Treatment of Sickle Cell Disease Cancer in Special Situations - Haematologic malignancies
10 Jul 2017 First-Line Nivolumab in Stage IV or Recurrent NSCLC with a PD-L1 Expression Level of 5% or More Lung and other thoracic tumours - Cancer Immunology and Immunotherapy - Anticancer agents & Biologic therapy
07 Jul 2017 FDA Grants Marketing Approval to the Praxis Extended RAS Panel Personalised medicine - Anticancer agents & Biologic therapy